ŠPINAROVÁ, Lenka. Studie LEADER (LEADER trial). Remedia. Praha: Medical Tribune, 2017, vol. 27, No 2, p. 170-171. ISSN 0862-8947.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Studie LEADER
Name (in English) LEADER trial
Authors ŠPINAROVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution).
Edition Remedia, Praha, Medical Tribune, 2017, 0862-8947.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/17:00096782
Organization unit Faculty of Medicine
Keywords (in Czech) diabetes mellitus; kardiovaskulární bezpečnost; liraglutid
Keywords in English diabetes mellitus; cardiovascular safety; liraglutide
Tags EL OK
Tags Reviewed
Changed by Changed by: Mgr. Vincent Belej, učo 7792. Changed: 15/3/2018 15:28.
Abstract
Studie LEADER sleduje kardiovaskulární bezpečnost liraglutidu u pacientů s diabetes mellitus a kardiovaskulárním onemocněním či s rizikem jeho vzniku. Prokázala jak účinnost, tak bezpečnost podání liraglutidu, včetně snížení celkové mortality pacientů.
Abstract (in English)
LEADER study investigates cardiovascular safety of liraglutide in patients with diabetes mellitus, and cardiovascular disease or at risk thereof. Study has proved the drug efficacy as well as the safety of its administration, including reduction of all-cause mortality.
PrintDisplayed: 26/8/2024 12:26